Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRUKER CORPORATION

(BRKR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BRUKER CORP : Change in Directors or Principal Officers (form 8-K)

08/20/2021 | 04:18pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 16, 2021, the Compensation Committee of Bruker Corporation (the "Company") approved an additional bonus opportunity for Dr. Mark Munch, EVP and President of the Bruker NANO Group. Such bonus opportunity will be separate from, and in addition to Dr. Munch's existing compensation arrangements and will be entirely tied to his new, additional role as CEO of the Company's majority-owned start-up company, Acuity Spatial Genomics, Inc.("Acuity"). Dr. Munch serves in this role at Acuity in addition to serving as Company EVP and President of the Bruker NANO Group.

The bonus opportunity for Dr. Munch consists of a combination of fixed and variable compensation over a five-year period beginning in the fiscal year ended December 31, 2021. The fixed component of the bonus arrangement consists of cash payments of $400,000 per year for service in years 2021 and 2022, $300,000 per year for service in years 2023 and 2024 and $200,000 for service in year 2025. Each of these cash amounts will be payable to Dr. Munch in the first quarter following each respective fiscal year, provided he was actively engaged as the CEO of Acuity through December 31st of that prior year.

The variable component of the bonus arrangement consists of Company performance stock units ("PSUs"), the value of which will be equal to 3.5% of the annual consolidated revenue of Acuity for each year between 2021 and 2025. For the years 2024 and 2025, Acuity must also achieve a minimum gross profit margin as a condition of the award of PSUs in each of those years. The PSUs, if earned, will be granted for each year between 2021 through 2025 in February of the following year, and will have a two-year vesting period from the date of grant.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about BRUKER CORPORATION
10/18BRUKER : Announces Date and Time of Third Quarter 2021 Earnings Release and Webcast
BU
10/01BRUKER : NSF-Funded Network for Advanced NMR Orders Two 1.1 GHz NMR Systems to Advance Pro..
BU
10/01Bruker Corporation Receives Orders for Two 1.1 Ghz NMR Avance Neo Systems from U.S. Aca..
CI
09/27BRUKER : Tony Keller Recognized for Extraordinary Achievements in NMR with the Otto-Stern ..
PU
09/07BRUKER : Joins PANACEA Network to Broaden Access to NMR for European Chemistry Community
PU
09/02BRUKER : Flexible Molecular Biology Software Solution Combines Cloud with Desktop Function..
PU
08/31BRUKER CORPORATION : Ex-dividend day for
FA
08/30BRUKER CORPORATION : to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
BU
08/20BRUKER CORP : Change in Directors or Principal Officers (form 8-K)
AQ
08/11INSIDER TRENDS : Bruker Insider Sells Shares for Tax Slowing 90-Day Buy Trend
MT
More news
Analyst Recommendations on BRUKER CORPORATION
More recommendations
Financials (USD)
Sales 2021 2 365 M - -
Net income 2021 254 M - -
Net Debt 2021 194 M - -
P/E ratio 2021 46,4x
Yield 2021 0,20%
Capitalization 11 831 M 11 831 M -
EV / Sales 2021 5,09x
EV / Sales 2022 4,74x
Nbr of Employees 7 400
Free-Float 58,3%
Chart BRUKER CORPORATION
Duration : Period :
Bruker Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRUKER CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 78,34 $
Average target price 84,90 $
Spread / Average Target 8,37%
EPS Revisions
Managers and Directors
Frank H. Laukien Chairman, President & Chief Executive Officer
Gerald N. Herman Chief Financial Officer & Executive Vice President
William Alderman Linton Lead Independent Director
Richard A. Packer Independent Director
Hermann Fritz Requardt Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BRUKER CORPORATION44.73%11 831
THERMO FISHER SCIENTIFIC30.62%240 757
DANAHER CORPORATION39.88%223 934
INTUITIVE SURGICAL, INC.25.24%122 004
SIEMENS HEALTHINEERS AG40.64%77 031
EDWARDS LIFESCIENCES CORPORATION26.87%72 674